Sector News

Sanofi signs up Evotec in 250M euro preclinical pact

December 3, 2014
Life sciences
Sanofi is deep in talks with Evotec about a five-year “multi-component strategic alliance” that would be worth at least 250 million euros to the German biotech.
 
The firms are holding “exclusive negotiations” about three initiatives, the most striking of which will see Evotec acquire Sanofi’s troubled operations in Toulouse “to build a European centre of excellence for compound management and drug discovery services”.
 
The French drugmaker had planned to run down operations at Toulouse but under pressure from the government and trades unions, in May 2013, it pledged to keep doing research at the site for five more years. Now some 200 of its scientists working in Toulouse will transfer to Evotec.
 
The proposed deal will also see Evotec license from Sanofi a portfolio including “five well-advanced pre-clinical projects in oncology” that will be progressed to the investigational new drug stage jointly before potential partnering. It also includes a “French academic bridge programme”.
 
The third element will see the companies combine their libraries to make them available for screening to Evotec’s partners. Sanofi’s library in Toulouse site has over one million compounds and this, added to Evotec’s 400,000 or so compounds, will create “a very large and valuable source of starting points for drug discovery”.
 
The 250 million euro figure includes a “sizeable upfront cash payment”, plus royalties. Werner Lanthaler, Evotec chief executive, said the collaboration “is a major milestone in the drug discovery space”. It also “accelerates Evotec’s strategy to become the leading drug discovery partner to the pharma and biotech industry as well as academia”.
 
Elias Zerhouni, head of R&D for the Paris-based giant, said  “open innovation is a key driver of Sanofi’s strategy” and Evotec is “a company that fits our quality expectations and our strategic vision”. He added that the collaboration “will secure the future for our employees in Toulouse and importantly accelerate our pipeline productivity”.
 
By Kevin Grogan
 
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).